1. Introduction {#sec1}
===============

Blood transfusion is an important therapeutic tool for patients with critical or malignant diseases. In the last several decades, many studies have shown that blood transfusion improves abnormalities in levels of blood components and increases patients\' ability to tolerate therapy, but short-term and long-term adverse effects have also been reported \[[@B1]\]. Several studies showed that components of transfused blood contain several factors that are important for the survival of tumor cells or perturb the recipient\'s immune system such as VEGF, PDGF-D, tissue plasminogen activator, TGF-*β*, IL-2, IFN-*γ*, and IL-10 \[[@B2]\]. In clinical studies, the effects of blood transfusion on survival in patients with solid tumors remain controversial \[[@B3]--[@B7]\].

In hematological malignancies, few studies have examined the relationship between blood transfusion and short-term or long-term adverse effects \[[@B8]--[@B10]\]. Jaime-Pérez et al. found that, in children with acute lymphoblastic leukemia (ALL), the number of blood products transfused correlated with poor survival, which may also reflect the severity of the disease \[[@B10]\]. In contrast, Alkayed et al. showed that blood transfusion did not correlate with overall survival (OS) or event-free survival (EFS) in children with ALL \[[@B8]\]. To date, we have not found any studies elucidating the relationship between blood transfusion and survival in patients with multiple myeloma (MM).

In the current study, we reviewed the medical records and follow-up data of newly diagnosed patients with MM in our single center to assess the correlation between blood transfusion on OS and progression-free survival (PFS) of newly diagnosed patients with MM without ASCT.

2. Materials and Methods {#sec2}
========================

2.1. Ethics Statement {#sec2.1}
---------------------

This study was approved by the ethics committee of Fujian Medical University Union Hospital. As this study was retrospective, written informed consent from patients was not sought.

2.2. Study Design {#sec2.2}
-----------------

A total of 181 newly diagnosed patients with MM without ASCT who had complete follow-up data between June 2010 and June 2015 at our hospital were included in this study.

2.3. Acquisition and Definition of Data {#sec2.3}
---------------------------------------

In this study, data were collected from the medical records of newly diagnosed patients with MM without ASCT from June 2010 to June 2015 at Fujian Medical University Union Hospital, Fujian, China. Patients who did not receive any therapeutic regimen or received ASCT or those without complete follow-up data were excluded.

Diagnosis and clinical event end points, such as disease progression and relapse, were evaluated by use of the International Myeloma Working Group criteria. OS was measured from the date of diagnosis to the date of death or last follow-up. Death from all causes was included. PFS was measured from the date on which the patient started treatment to the date of disease progression, relapse, or death, whichever came first. Survival time was measured until 31 December 2015.

Patients that received more than 2 units of packed red blood cells (RBC) and/or more than 1 unit (≥2 × 10^11^ platelets per unit) of apheresis platelets (Plt) and/or more than 15 mL/kg of fresh frozen plasma (FFP) during induction, consolidation, and maintenance therapy were categorized as blood transfusion group. All blood products were leukocyte-reduced (leukocyte number \< 5 × 10^5^). The storage duration of RBC units ranged from 7 days to 21 days. The storage duration of Plt units and FFP was limited to 5 days and one year, respectively. The decisions to transfuse in patients with MM were made based on the treating doctors\' judgment and guided by our hospital\'s technical manual of clinical blood transfusion \[[@B1]\]. Technical manuals of clinical blood transfusion in our hospital were listed briefly as follows: the RBC transfusion threshold is 60 g/L of hemoglobin, the plasma transfusion threshold is 1.3 times the upper limit of normal or 1.5 times the midpoint of the reference range in standard coagulation screening tests, and the prophylactic Plt transfusion threshold is 10 × 10^9^/L.

2.4. Statistical Analyses {#sec2.4}
-------------------------

Demographic and clinicopathological characteristics were compared between the blood transfusion group and the no-blood transfusion group using the chi-squared test for categorical variables and independent*t*-test for continuous variables. The Kaplan-Meier method was used to calculate survival for PFS and OS, and the log-rank test was used to analyze the significance of differences among these survival curves. Cox regression models were performed for multivariate analyses with adjustments for characteristics that might be significant prognostic factors according to the univariate analyses. All statistical analyses were performed using SPSS 19.0 software. Two-sided *P* values of \<0.05 were used as the criterion for statistical significance.

3. Results {#sec3}
==========

3.1. Characteristics of Transfused and Nontransfused Groups {#sec3.1}
-----------------------------------------------------------

A total of 181 newly diagnosed inpatients with MM without ASCT were included. The median follow-up interval of all patients was 20.03 (range from 0.3 to 66.73) months. During the follow-up period, 79 deaths occurred.

The demographic and clinicopathological characteristics of all patients before treatment are listed in [Table 1](#tab1){ref-type="table"}. Of the 181 inpatients, 68 patients (37.57%) received a blood transfusion and 113 patients (62.43%) did not. Erythropoiesis-stimulating agents (ESAs) were not used in all 181 patients.

The transfused patients had higher ECOG scores, lower platelet (Plt) counts, lower hemoglobin (Hb) levels, higher serum creatinine (Scr) levels, and higher serum *β*~2~-microglobulin (*β*~2~-MG) levels than nontransfused patients. There was a significant difference in Ig isotype between transfused and nontransfused patients. In the therapeutic regimens that followed their diagnosis, the patients in the transfused group received more bortezomib than nontransfused patients. There were no significant differences in age, gender, ISS staging, serum albumin (Alb) level, serum lactate dehydrogenase (LDH) level, serum calcium (Ca) level, or thalidomide use between the two groups ([Table 1](#tab1){ref-type="table"}).

3.2. Univariate and Multivariate Analyses {#sec3.2}
-----------------------------------------

Univariate analyses showed that, in all 181 patients without ASCT, patients with age ≥ 60, higher ISS staging, Plt counts \< 100 × 10^9^/L, Scr level ≥ 177 *μ*mol/L, serum *β*~2~-MG ≥ 5.5 *μ*mol/L, or serum Ca ≥ 2.75 mmol/L had shorter OS than others in the cohort. Patients who received thalidomide had longer OS. Blood transfusion was not associated with OS in patients with MM ([Table 2](#tab2){ref-type="table"}, [Figure 1(a)](#fig1){ref-type="fig"}).

With respect to PFS in all 181 patients without ASCT, patients with higher ISS staging, Plt counts \< 100 × 10^9^/L, Scr level ≥ 177 *μ*mol/L, serum *β*~2~-MG ≥ 5.5 *μ*mol/L, and serum Ca ≥ 2.75 mmol/L and those who received a blood transfusion had shorter PFS. Patients who were treated with thalidomide had longer PFS. Additionally, Ig isotype was associated with PFS ([Table 2](#tab2){ref-type="table"}, [Figure 1(b)](#fig1){ref-type="fig"}).

Multivariate analyses showed that age ≥ 60, Plt counts \< 100 × 10^9^/L, serum Ca ≥ 2.75 mmol/L, and thalidomide treatment were independent prognostic factors for OS in patients with MM. Moreover, Ig isotype and thalidomide application were independent prognostic factors for PFS in patients with MM. Blood transfusion was not an independent prognostic factor for PFS in patients with MM ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

MM is an incurable plasma cell disease characterized by the proliferation of malignant monoclonal plasma cells in the bone marrow and accounts for 10% of hematological malignancies. This proportion is expected to increase because of the aging population \[[@B11]\]. Inhibition of hematopoietic function in the bone marrow induced by the proliferation of malignant monoclonal plasma cells and treatment with chemotherapy increased the likelihood of requiring a blood transfusion. Therefore, blood transfusion is an important component of MM therapy.

Several studies have shown that stored blood contains factors that may regulate immune cells, leading to immunosuppression, or promote the survival of tumor cells \[[@B2]\]. However, the effect of blood transfusion on the survival of patients with malignant diseases remains controversial \[[@B3]--[@B8], [@B10]\]. In the solid tumor literature, several studies found that red blood cell transfusion is an independent poor prognostic factor for survival in patients with cancer of the digestive, urinary, or respiratory systems \[[@B3], [@B5], [@B6], [@B12]--[@B15]\]. However, others reported that blood transfusion does not affect survival in patients with gastric or renal cell cancer \[[@B4], [@B7]\]. The effects of transfusion are equally unclear in patients with hematological malignancies \[[@B8], [@B10]\], such as acute lymphoblastic leukemia as above. Prior to this work, there were no reports on the impact of blood transfusion on survival in patients with MM.

Since ASCT may increase the requirement for blood transfusion, we included 181 newly diagnosed patients with MM who had complete follow-up data and who did not undergo ASCT. Thirty-two newly diagnosed patients with complete follow-up data were excluded because they underwent ASCT. In the current study, we found that, for patients with MM without ASCT, age ≥ 60, higher ISS staging, Plt counts \< 100 × 10^9^/L, Scr level ≥ 177 *μ*mol/L, serum *β*~2~-MG ≥ 5.5 *μ*mol/L, serum Ca ≥ 2.75 mmol/L, and the use of thalidomide were correlated with OS, whereas blood transfusion was not associated. In contrast, blood transfusion was associated with PFS in patients with MM without ASCT, as were higher ISS staging, Plt counts \< 100 × 10^9^/L, Scr level ≥ 177 *μ*mol/L, serum *β*~2~-MG ≥ 5.5 *μ*mol/L, serum Ca ≥ 2.75 mmol/L, and treatment with thalidomide.

Multivariate analysis showed that blood transfusion is not an independent prognostic factor for PFS in patients with MM without ASCT. After analyzing the characteristics of our cohort, we concluded that, compared with the group of patients who did not require transfusion, higher ISS staging, lower Hb and Plt levels, and renal dysfunction in blood transfusion group led to the requirement for blood transfusion and the lower PFS. Meanwhile, the negative effect of blood transfusion on survival in patients with MM was attenuated by the benefit of bortezomib usage, causing there to be no significant difference in OS between the group that received transfusions and the group that did not. This argument is strengthened by the finding that bortezomib was used at a higher rate in the transfused group than in the nontransfused group, and survival in patients with MM without ASCT is significantly improved by bortezomib \[[@B16]\]. However, lack of data of some important prognostic factors such as fluorescence in situ hybridization (FISH) or cytogenetics in our cohort may influence the results of univariate and multivariate survival analysis. Moreover, hematopoietic failure induced by bortezomib usage may lead to higher transfusion needs, which may influence the analysis of the relationship between blood transfusion and survival in MM patients.

Blood transfusion is an important therapeutic method for patients with MM who are receiving chemotherapy. Hypoxia induced by severe anemia may decrease patients\' tolerance to chemotherapy, influence the cytotoxic effect of some drugs such as cyclophosphamide and doxorubicin, and reduce the sensitivity of tumor cells to chemotherapeutics \[[@B17]\]. Meanwhile, protein in plasma may act as a drug carrier and may also influence the metabolism and cytotoxicity of drugs in vivo \[[@B18], [@B19]\]. Currently, the guidelines regarding thresholds for blood transfusion, including RBC, differ by country. In China, the RBC transfusion threshold is 60 g/L of hemoglobin in nonsurgical patients and 70 g/L of hemoglobin in surgical patients. However, in the United States, a threshold of 70 to 80 g/L of hemoglobin is recommended for patients without underlying cardiac disease, and a threshold of 80 g/L of hemoglobin or less is recommended for patients with underlying cardiac disease \[[@B1]\]. In American and Chinese guidelines, the patient\'s clinical situation and response to anemia should be taken into account in the decision to transfuse RBC. Similar problems exist with transfusion of other blood products. In our study, though blood transfusion was associated with decreased PFS in patients with MM, it was not an independent negative factor for PFS and OS. Due to the lack of much important data, such as FISH or cytogenetics, relevant to MM patients\' prognosis in our cohort, effect of bortezomib on survival and blood transfusion, and the indefinite effects of blood transfusion on survival in patients with tumors \[[@B3]--[@B7]\], we think that a prospective study including MM patients who have sufficient data of clinical characteristics and more comparable therapy is needed to evaluate the effects of blood transfusion on MM patients, in order to develop a liberal or restricted transfusion strategy used for decisions about blood transfusion in patients with MM.

In recent years, some studies showed that usage of ESAs could increase the hemoglobin level of MM patients with good tolerance during chemotherapy and might lead to the reduction of RBC transfusion \[[@B20], [@B21]\]. So, ESAs are recommended as an adjunct to transfusions or alternative in MM therapy to increase the patients\' tolerance to chemotherapy and decrease the consumption of blood products.
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###### 

Demographic and clinicopathological characteristics of MM patients before treatment.

  -----------------------------------------------------------------------------------
  Characteristic                           Transfused\      Nontransfused\    *P*
                                           (*n* = 68) (%)   (*n* = 113) (%)   
  ---------------------------- ----------- ---------------- ----------------- -------
  Age                          ≥60         40 (58.8)        60 (53.1)         0.537

  \<60                         28 (41.2)   53 (46.9)                          

  Gender                       Male        38 (55.9)        76 (67.3)         0.153

  Female                       30 (44.1)   37 (32.7)                          

  Ig isotype                   IgG         40 (58.8)        57 (50.4)         0.208

  IgA                          18 (26.5)   29 (25.7)                          

  Light chain                  10 (14.7)   21 (18.6)                          

  Others                       0 (0)       6 (5.3)                            

  ISS staging                  I           5 (7.4)          26 (23.0)         0.006

  II                           31 (45.6)   55 (48.7)                          

  III                          32 (47.0)   32 (28.3)                          

  ECOG                         0-1         52 (76.5)        101 (89.4)        0.020

  2--4                         16 (23.5)   12 (10.6)                          

  Plt (×10^9^/L)               ≥100        52 (76.5)        104 (92.0)        0.003

  \<100                        16 (23.5)   9 (8.0)                            

  Hb (g/L)                     ≥100        6 (8.8)          49 (43.4)         0.000

  \<100                        62 (91.2)   64 (56.6)                          

  Scr (*μ*mol/L)               ≥177        24 (35.3)        15 (13.3)         0.001

  \<177                        44 (64.7)   98 (86.7)                          

  Serum Alb (g/L)              ≥35         13 (19.1)        36 (31.9)         0.062

  \<35                         55 (80.9)   77 (68.1)                          

  Serum *β*~2~-MG (*μ*mol/L)   ≥5.5        32 (47.0)        32 (28.3)         0.011

  \<5.5                        36 (53.0)   81 (71.7)                          

  Serum LDH (IU/L)             ≥245        14 (20.6)        14 (12.4)         0.140

  \<245                        54 (79.4)   99 (87.6)                          

  Serum Ca (mmol/L)\           ≥2.75       11 (16.2)        10 (8.8)          0.136

  \<2.75                       57 (83.8)   103 (91.2)                         

  Bortezomib                   Yes         51 (75.0)        60 (53.1)         0.003

  No                           17 (25.0)   53 (46.9)                          

  Thalidomide                  Yes         54 (79.4)        90 (79.6)         0.970

  No                           14 (20.6)   23 (20.4)                          
  -----------------------------------------------------------------------------------

Ig: immunoglobulin; ISS: International Staging System; ECOG: Eastern Cooperative Oncology Group; Plt: platelet; Hb: hemoglobin; Scr: serum creatinine; Alb: albumin; *β*~2~-MG: *β*~2~-microglobulin; LDH: lactate dehydrogenase; Ca: calcium.

###### 

Univariate analysis of the correlation between demographic and clinicopathological characteristics and survival time in patients with MM.

  Characteristics                      *n*      OS (mean)   PFS (mean)
  ---------------------------- ------- -------- ----------- ------------
  Age                          ≥60     100      20.355      16.595
  \<60                         81      28.233   20.102      
  Gender                       Male    114      23.614      18.322
  Female                       67      24.333   17.897      
  Ig isotype                   IgG     97       22.531      16.210
  IgA                          47      24.419   19.674      
  Light chain                  31      21.914   18.971      
  Others                       6       51.645   33.772      
  ISS staging                  I       31       29.096      22.806
  II                           86      28.490   21.231      
  III                          64      15.161   11.796      
  ECOG                         0-1     153      25.098      18.830
  2--4                         28      17.230   14.531      
  Plt (×10^9^/L)               ≥100    156      25.251      19.403
  \<100                        25      15.327   10.440      
  Hb (g/L)                     ≥100    55       22.732      21.187
  \<100                        126     26.511   16.846      
  Scr (*μ*mol/L)               ≥177    39       13.888      10.382
  \<177                        142     26.625   20.302      
  Serum Alb (g/L)              ≥35     49       25.292      20.049
  \<35                         132     23.357   17.465      
  Serum *β*~2~-MG (*μ*mol/L)   ≥5.5    64       15.161      11.796
  \<5.5                        117     28.650   21.648      
  Serum LDH (IU/L)             ≥245    28       18.717      14.700
  \<245                        153     24.826   18.799      
  Serum Ca (mmol/L)            ≥2.75   21       13.268      11.910
  \<2.75                       160     25.273   18.986      
  Bortezomib                   Yes     111      24.816      18.957
  No                           70      22.398   16.909      
  Thalidomide                  Yes     144      26.712      20.368
  No                           37      12.860   9.590       
  Blood transfusion            Yes     68       22.376      14.998
  No                           113     24.786   20.070      

###### 

Multivariate analysis of the correlation between demographic and clinicopathological characteristics and survival time in patients with MM.

  Covariates              Overall survival   Progression-free survival                  
  ----------------------- ------------------ --------------------------- -------------- -------
  Age                     1.005--1.038       0.011                       N/A            N/A
  Ig isotype              N/A                N/A                         0.659--0.957   0.015
  ISS staging             0.697--1.661       0.740                       0.694--1.648   0.761
  Plt (×10^9^/L)          0.369--0.939       0.026                       0.409--1.084   0.102
  Scr (*μ*mol/L)          0.977--2.453       0.063                       0.975--2.501   0.063
  *β* ~2~-MG (*μ*mol/L)   0.665--2.524       0.447                       0.849--3.244   0.138
  Ca (mmol/L)             1.172--3.389       0.011                       0.838--2.279   0.205
  Thalidomide             0.277--0.612       0.000                       0.286--0.641   0.000
  Blood transfusion       N/A                N/A                         0.735--1.453   0.849

ISS: International Staging System; Scr: serum creatinine; *β*~2~-MG: *β*~2~-microglobulin; Ca: calcium; HR: hazard ratio; CI: confidence interval; N/A: not available.
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